Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04182204
Title A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

diffuse large B-cell lymphoma

Therapies

Gemcitabine + Oxaliplatin + Rituximab

Gemcitabine + Oxaliplatin + Polatuzumab vedotin-piiq + Rituximab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.